Neuromodulation Business Overview

Neuromodulation accounted for $1.3 billion, or 10%, of Medtronic's $13.5 billion in revenue in FY2008.

FY2008 Global Revenue
Neuromodulation accounted for $1.3 billion, or 10%, of Medtronic's $13.5 billion in revenue in FY2008.

Neuromodulation is the second-oldest and fourth-largest of Medtronic's business units. It was formed as we transferred our expertise in heart electrical stimulation to treat diseases and conditions involving the nervous system. Today, our products include neurostimulation systems and implantable drug delivery systems for chronic pain, common movement disorders, and urologic and gastrointestinal disorders.

Our products include:

  • Deep brain stimulation therapy systems use an implanted neurostimulation system to stimulate specific targets in the brain to manage some of the symptoms associated with Parkinson's disease, essential tremor, and dystonia. Stimulation can be noninvasively adjusted to meet each patient's needs.
  • Pain management therapies from our neurostimulation and drug delivery areas. Neurostimulation and intrathecal drug delivery may be options for patients with pain who are experiencing inadequate pain relief or uncomfortable side effects from their current pain treatments.
  • Sacral nerve stimulation for faecal and urinary incontinence is an implantable treatment using electrical stimulation of the sacral nerves to manage the symptoms of faecal or urinary incontinence.
  • Intrathecal baclofen therapy (ITB therapy) may help to ease intractable spasticity in patients with cerebral palsy by delivering medication directly to the intrathecal space in small, precisely controlled doses using a pump that is surgically placed in the abdomen.

 

Last updated: 27 Sep 2010

Section Navigation

Additional information

NYSE (MDT)

Australasia